Army Antimalarial Drug Development: An Advanced Development Case Study for Tafenoquine

Area of Science:

• Medical Countermeasures
• Infectious Disease Research
• Pharmaceutical Development

Background:

• Malaria poses a significant mortality risk to U.S. service members deployed overseas.
• Increasing antimalarial drug resistance necessitates the development of new prevention and treatment options.
• The U.S. Army Medical Materiel Development Activity (USAMMDA) is addressing this threat.

Purpose of the Study:

• To outline the development strategies for the antimalarial drug tafenoquine.
• To highlight USAMMDA's role in managing tafenoquine's medical product development.
• To emphasize the importance of industry partnerships in drug development.

Main Methods:

• Managing the medical product development pipeline for tafenoquine.
• Leveraging industry expertise and manufacturing capabilities.
• Translating Department of Defense capability gaps into commercial products.

Main Results:

• Tafenoquine is an effective prophylactic drug against all human malaria species and parasite life stages.
• Tafenoquine provides broad capabilities for both malaria prophylaxis and treatment in a single drug.
• Industry partnerships are crucial for achieving drug licensure and commercial availability.

Conclusions:

• Tafenoquine represents a critical advancement in antimalarial drug development.
• Strategic partnerships accelerate the availability of essential medical countermeasures.
• USAMMDA's approach ensures a robust pipeline of next-generation antimalarial drugs.